In this line, there are two ongoing clinical trials to evaluate the therapeutic benefit and safety of β3-AR agonist in patients with HF with preserved LVEF (NCT 02599480) [52] and reduced LVEF (NCT01876433). Here, ADRB3 is linked to hydrops fetalis.